Yersinia enterocolitica - Xen24 bioluminescent pathogenic bacteria for in vivo and in vitro drug discovery. This product was derived from the 91A1854 clinical isolate. Y. enterocolitica-Xen24 possesses a stable copy of the Photorhabdus luminescens lux operon on the bacterial chromosome.
Infectious disease is a perennially important area for both life science research and drug discovery. Some of the first applications of IVIS® imaging technology were in tracking infections and monitoring host responses, and these applications are still at the forefront of research. PerkinElmer's bioluminescent infectious disease light-producing microorganisms have been developed to mimic both acute and chronic standard infection protocols presently used by researchers.
· Engineered Bacterium: Yersinia enterocolitica - Xen24
· Parental Strain: 91A1854 clinical isolate
· In Vitro/Ex Vivo: Growth profiles
· In Vivo: Not tested
Advantages of using bioluminescent light-producing microorganisms for drug discovery in vitro:
· Rapid and readily amenable to high throughput screening, e.g., 96 or 384-well format
· Sensitivity - subtle changes in cellular viability are rapidly detected
· Inexpensive - no additional substrates needed for bacterial assays
Advantages of using bioluminescent light-producing microorganisms for drug discovery in vivo:
· Rapid identification of lead drug candidates
· Real-time efficacy data
· May help to decrease drug failure by allowing disease relapse to be monitored in the same animal
For laboratory use only. This product is intended for animal research only and not for use in humans.